• 1
    Matutes E, Brito-Babapulle V, Swansbury J, et al.Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia.Blood.1991;78:32693274.
  • 2
    Soulier J, Pierron G, Vecchione D, et al.A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia.Genes Chromosomes Cancer.2001;31:248254.
  • 3
    Herling M, Khoury JD, Washington LT, Duvic M, Keating MJ, Jones D.A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories.Blood.2004;104:328335.
  • 4
    Herling M, Patel KA, Teitell MA, et al.High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.Blood.2008;111:328337.
  • 5
    Catovsky D.Prolymphocytic leukaemia.Nouv Rev Fr Hematol.1982;24:343347.
  • 6
    Pawson R, Dyer MJ, Barge R, et al.Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.J Clin Oncol.1997;15:26672672.
  • 7
    Dearden CE, Matutes E, Cazin B, et al.High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.Blood.2001;98:17211726.
  • 8
    Keating MJ, Cazin B, Coutré S, et al.Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.J Clin Oncol.2002;20:205213.
  • 9
    Elter T, Borchmann P, Schulz H, et al.Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.J Clin Oncol.2005;23:70247031.
  • 10
    Kennedy B, Rawstron A, Carter C, et al.Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia.Blood.2002;99:22452247.
  • 11
    Stilgenbauer S, Zenz T, Winkler D, et al; German Chronic Lymphocytic Leukemia Study Group.Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.J Clin Oncol.2009;27:39944001.
  • 12
    Eichhorst BF, Busch R, Hopfinger G, et al; German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.Blood.2006;107:885891.
  • 13
    Bosch F, Ferrer A, López-Guillermo A, et al;GELCAB (Grup per l'Estudi dels Limfomes a Catalunya i Balears). Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia.Br J Haematol.2002;119:976984.
  • 14
    Hillmen P, Cohen DR, Cocks K, et al;NCRI CLL Sub-Group. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.Br J Haematol.2011;152:570578.
  • 15
    Swerdlow SH, Campo E, Harris NL, et al, editors.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition.Lyon, France:International Agency for Research on Cancer;2008.
  • 16
    Gesk S, Martin-Subero JI, Harder L, et al.Molecular cytogenetic detection of chromosomal breakpoints in T-cell receptor gene loci.Leukemia.2003;17:738745.
  • 17
    Cheson BD, Bennett JM, Grever M, et al.National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.Blood.1996;87:49904997.
  • 18
    Ravandi F, O'Brien S, Jones D, et al.T-cell prolymphocytic leukemia: a single-institution experience.Clin Lymphoma Myeloma.2005;6:234239.
  • 19
    Dohner H, Ho AD, Thaler J, et al.Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group.J Natl Cancer Inst.1993;85:658662.
  • 20
    Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D.The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype.J Clin Oncol.1994;12:25882593.
  • 21
    Maeda A, Iwai K, Ishibashi T.Successful treatment of T-cell prolymphocytic leukemia (T-PLL) with fludarabine monophosphate [in Japanese].Rinsho Ketsueki.2009;50:658662.
  • 22
    Ravandi F, Aribi A, O'Brien S, et al.Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.J Clin Oncol.2009;27:54255430.
  • 23
    Dearden CE, Khot A, Else M, et al.Alemtuzumab therapy in T-cell prolymphocytic leukaemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route.Blood.2011;118:57995802.
  • 24
    Krishnan B, Else M, Tjonnfjord GE, et al.Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.Br J Haematol.2010;149:907910.
  • 25
    Wiktor-Jedrzejczak W, Dearden C, de Wreede L, et al;EBMT Chronic Leukemia Working Party. Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium.Leukemia.2012;26:972976.
  • 26
    O'Brien SM, Keating MJ, Mocarski ES.Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.Clin Lymphoma Myeloma.2006;7:125130.
  • 27
    Weidmann E, Hess G, Chow KU, et al.A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.Leuk Lymphoma.2010;51:447455.
  • 28
    Lundin J, Kennedy B, Dearden C, Dyer MJ, Osterborg A.No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome.Blood.2005;105:41484149.
  • 29
    Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M.Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.Blood.2004;104:655658.
  • 30
    Yeh ET, Tong AT, Lenihan DJ, et al.Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.Circulation.2004;109:31223131.